Cardax, Inc.

CDXI

US14141D2018

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 09:38:51 2023-12-27 am EST			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-.--%

2021	Cardax, Inc. announced a financing transaction	CI
2021	Cardax, Inc. Announces Restructuring of Board of Directors	CI

Cardax, Inc. Reports Revenue Results for the First Quarter of 2018

May 09, 2018 at 08:00 am EDT

Cardax, Inc. reported revenue results for the first quarter of 2018. The company's revenues from sales of ZanthoSyn®, its premium astaxanthin dietary supplement for inflammatory health and longevity, increased almost three-fold from $107,990 in first quarter of 2017 to $313,310 in first quarter of 2018.

Latest news about Cardax, Inc.

Cardax, Inc. announced a financing transaction	21-09-15	CI
Cardax, Inc. Announces Restructuring of Board of Directors	21-08-31	CI
Cardax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-14	CI
Cardax, Inc. announced that it expects to receive $10 million in funding from US Capital Global Investment Management, LLC	21-01-10	CI
Cardax, Inc. announced that it expects to receive $10 million in funding	20-11-17	CI
Cardax, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-13	CI
Cardax, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-14	CI
Cardax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-15	CI
Cardax, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-30	CI
Cardax, Inc. announced that it expects to receive $0.46 million in funding	20-03-15	CI
Cardax, Inc. has Changed its Ticker to CDXI from CDXID	20-02-03	CI
Cardax, Inc. announced that it expects to receive $0.25 million in funding from Harbor Gates Capital, LLC	20-01-20	CI
Cardax, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-14	CI
Cardax Announces Interim Results from CHASE Clinical Trial	19-09-23	CI
Cardax, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-14	CI
Cardax, Inc. announced that it has received $0.75 million in funding	19-07-18	CI
Cardax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-15	CI
Cardax, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	19-03-28	CI
Cardax, Inc. Announces CHASE Clinical Trial Initiated- Rx Development Plans for CDX-101 and CDX-301	19-03-28	CI
Cardax, Inc. Names Paresh N. Soni as Chief Clinical and Regulatory Strategist and Member of Scientific Advisory Board	18-11-28	CI
Cardax, Inc. Announces Sales Results for the Third Quarter and Nine Months of 2018	18-11-13	CI
Cardax, Inc. Launches Human Clinical Trial Targeting Cardiovascular Inflammatory Health	18-10-02	CI
Cardax, Inc. Announces Sales Results for the Second Quarter of 2018	18-08-13	CI
Cardax, Inc. Announces Board Appointments	18-06-01	CI
Cardax, Inc. Reports Revenue Results for the First Quarter of 2018	18-05-09	CI

Chart Cardax, Inc.

Duration

Period

More charts

Company Profile

Cardax, Inc. is a consumer health company focused on marketing ZanthoSyn, an astaxanthin dietary supplement for inflammatory health. It seeks to monetize CDX-101, the Company's pre-clinical pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, and CDX-301, the Company's pre-clinical pharmaceutical candidate for macular degeneration. CDX-101 is a proprietary astaxanthin prodrug that cleaves following oral administration and delivers astaxanthin to the bloodstream. Astaxanthin is a naturally occurring molecule with safe anti-inflammatory activity that supports cardiovascular health, metabolic health, liver health, joint health, and longevity. It intends to develop zeaxanthin pharmaceutical candidate, CDX-301, for macular degeneration. Zeaxanthin accumulates in the human eye through uptake by a retinal receptor, providing protection against blue light, oxidative damage, and related inflammation that occurs in macular degeneration.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CARDAX, INC.	-.--%	0
NOVO NORDISK A/S	+31.37%	588B
JOHNSON & JOHNSON	-2.60%	364B
MERCK & CO., INC.	+20.83%	326B
ABBVIE INC.	+5.69%	285B
ASTRAZENECA PLC	+14.83%	239B
NOVARTIS AG	+9.93%	210B
ROCHE HOLDING AG	-6.95%	200B
AMGEN INC.	+10.77%	167B
PFIZER, INC.	+0.10%	161B

Other Pharmaceuticals

Cardax, Inc.

Equities

CDXI

US14141D2018

Pharmaceuticals

Cardax, Inc. Reports Revenue Results for the First Quarter of 2018

Latest news about Cardax, Inc.

Chart Cardax, Inc.

Company Profile

Sector Other Pharmaceuticals